Browsing by Author "Sehouli, Jalid"

Now showing 1 - 5 of 5

ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
(2022) Colombo, Nicoletta; Coleman, Robert L.; Wu, Xiaohua; Kose, Fatih; Wenham, Robert Michael; Sebastianelli, Alexandra; Hasegawa, Kosei; Zsiros, Emese; Rouge, Thibault De la Motte; Bidzinski, Mariusz; McNeish, Iain A.; Sehouli, Jalid; Korach, Jacob; Debruyne, Philip R.; Kim, Jae-Weon; De Melo, Andrea C.; Peng, Xuan; Bogusz, Agata M.; Yamada, Karin Sayuri; Monk, Bradley J.
Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies
(2021) Gungorduk, Kemal; Muallem, Jumana; Asicioglu, Osman; Gulseren, Varol; Gulec, Umran Kucukgoz; Meydanli, Mehmet Mutlu; Sehouli, Jalid; Ozdemir, Aykut; Sahin, Hanifi; Khatib, Ghanim; Miranda, Andrea; Boran, Nurettin; Senol, Taylan; Yildirim, Nuri; Turan, Taner; Ozge, Tufan; Taskin, Salih; Vardar, Mehmet Ali; Ayhan, Ali; Muallem, Mustafa Zelal; 34448946
Aim This multicenter investigation was performed to evaluate the adjuvant treatment options, prognostic factors, and patterns of recurrence in patients with grade 3 endometrioid endometrial cancer (G3-EEC). Materials and methods The medical reports of patients undergoing at least total hysterectomy and salpingo-oophorectomy for G3-EEC between 1996 and 2018 at 11 gynecological oncology centers were analyzed. Optimal surgery was defined as removal of all disease except for residual nodules with a maximum diameter <= 1 cm, as determined at completion of the primary operation. Adequate systematic lymphadenectomy was defined as the removal of at least 15 pelvic and at least 5 paraaortic LNs. Results The study population consists of 465 women with G3-EEC. The 5-year disease-free survival (DFS) and overall survival (OS) rates of the entire cohort are 50.3% and 57.6%, respectively. Adequate systematic lymphadenectomy was achieved in 429 (92.2%) patients. Optimal surgery was achieved in 135 (75.0%) patients in advanced stage. Inadequate lymphadenectomy (DFS; HR 3.4, 95% CI 3.0-5.6; P = 0.016-OS; HR 3.2, 95% CI 1.6-6.5; P = 0.019) was independent prognostic factors for 5-year DFS and OS. Conclusion Inadequate lymphadenectomy and LVSI were independent prognostic factors for worse DFS and OS in women with stage I-II G3-EEC. Adequate lymphadenectomy and optimal surgery were independent prognostic factors for better DFS and OS in women with stage III-IV G3-EEC.
Trial in Progress of Engot-Cx8/Gog-3024/Innovatv 205: Addition of A New Cohort Using First-Line Tisotumab Vedotin Plus Pembrolizumab Plus Carboplatin +/- Bevacizumab in Recurrent/Metastatic Cervical Cancer
(2022) Vergote, Ignace; Mirza, Mansoor; Sehouli, Jalid; Lorusso, Domenica; Kose, Fatih; Cibula, David; Westermann, Anneke; Collins, Dearbhaile; Banerjee, Susana; Oaknin, Ana; Soumaoro, Ibrahima; Jain, Shweta; Monk, Bradley
Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)
(2022) Vergote, Ignace; Mirza, Mansoor Raza; Sehouli, Jalid; Lorusso, Domenica; Ose, Fatih K.; Cibula, David; Westermann, Anneke M.; Collins, Dearbhaile Catherine; Banerjee, Susana N.; Oaknin, Ana; Soumaoro, Ibrahima; Jain, Shweta; Monk, Bradley J.
Trial in Progress Update on Engotcx8/Gog-3024/Innovatv 205: Addition of A New Cohort Using First-Line Tisotumab Vedotin Plus Pembrolizumab Plus Carboplatin - Bevacizumab in Recurrentimetastatic Cervical Cancer
(2022) Vergote, Ignace; Mirza, Mansoor; Sehouli, Jalid; Lorusso, Domenico; Kose, Fatih; Cibula, David; Westermann, Anneke; Collins, Dearbhaile; Banerjee, Susana; Oaknin, Ana; Soumaoro, Ibrahima; Jain, Shweta; Monk, Bradley J.